ACADIA Pharmaceuticals Inc. (ACAD) fair value analysis

Nasdaq · Updated 2026-09-07

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes medicines for central nervous system disorders, including schizophrenia, depression, and other psychiatric and neurological conditions. The company operates in the United States and international markets, conducting research, development, and sales activities across multiple regions.

Forward Fair Value verdict

Overvalued

Based on TickrTrends' weekly Forward Fair Value model, ACAD is trading at more than a 25% premium to estimated fair value.

ACAD currently ranks #111 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Overvalued for 3 consecutive weekly runs.

Last price: $25.61
Sector: Healthcare
12-month range: $21.24–$26.29

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: A
Leverage: Low
Margin trend: Stable
Revenue growth: High
RSI zone: Neutral
50/200-day trend: Mixed
52-week position: The top quarter of its range

What our data shows for ACAD

Our model validated 9 trailing price-to-earnings windows for ACAD, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $21.24–$26.29.
The 14-day relative strength index sits at a neutral 43.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for ACAD
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent ACAD news

TickrTrends' derived news-sentiment signal for ACAD is currently leaning positive, computed from recent coverage.

ACAD Maintained by Deutsche Bank -- Price Target Raised to $38.00 (gurufocus.com, 2026-08-25)
TickrTrends take: Deutsche Bank's price target raise to $38 comes amid TickrTrends' current overvalued assessment of ACAD, suggesting the market may already be pricing in positive expectations for the healthcare company. Investors tracking valuation metrics should monitor whether ACAD's fundamentals can justify closing the gap between current trading levels and Deutsche Bank's target, or whether the overvaluation verdict will persist. The analyst action provides a data point for reconciling with TickrTrends' valuation framework, particularly as healthcare sector dynamics continue to evolve.
Acadia Pharmaceuticals: Another Bite At The Alzheimer's Apple (NASDAQ:ACAD) (seekingalpha.com, 2026-08-24)
TickrTrends take: Acadia Pharmaceuticals continues to pursue opportunities in the Alzheimer's disease market, an area of significant pharmaceutical development activity. Given TickrTrends' current assessment that ACAD is overvalued, investors focused on valuation metrics should monitor whether the company's pipeline progress and clinical data justify its current market price relative to peers in the Healthcare sector. The company's ability to advance its Alzheimer's programs will be critical to determining whether the current valuation reflects genuine competitive advantage or represents a premium that may not be supported by near-term commercial prospects.

What people are saying

Follow the ACAD conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is ACAD stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), ACAD is trading at more than a 25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.

What is ACAD's TickrTrends verdict?

ACAD's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.

How does ACAD compare to other Healthcare stocks?

ACAD ranks #111 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is ACAD overbought or oversold?

ACAD's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

ACAD vs ALKS · ACAD vs AMGN · ACAD vs CDNA · ACAD vs DGX · ACAD vs GILD